Cargando…
The dark side of opioids in pain management: basic science explains clinical observation
INTRODUCTION: In the past 2 decades, opioids have been used increasingly for the treatment of persistent pain, and doses have tended to creep up. As basic science elucidates mechanisms of pain and analgesia, the cross talk between central pain and opioid actions becomes clearer. OBJECTIVES: We aimed...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5741356/ https://www.ncbi.nlm.nih.gov/pubmed/29392193 http://dx.doi.org/10.1097/PR9.0000000000000570 |
_version_ | 1783288183298981888 |
---|---|
author | Rivat, Cyril Ballantyne, Jane |
author_facet | Rivat, Cyril Ballantyne, Jane |
author_sort | Rivat, Cyril |
collection | PubMed |
description | INTRODUCTION: In the past 2 decades, opioids have been used increasingly for the treatment of persistent pain, and doses have tended to creep up. As basic science elucidates mechanisms of pain and analgesia, the cross talk between central pain and opioid actions becomes clearer. OBJECTIVES: We aimed to examine the published literature on basic science explaining pronociceptive opioid actions, and apply this knowledge to clinical observation. METHODS: We reviewed the existing literature on the pronociceptive actions of opioids, both preclinical and clinical studies. RESULTS: Basic science provides a rationale for the clinical observation that opioids sometimes increase rather than decrease pain. Central sensitization (hyperalgesia) underlies pain chronification, but can also be produced by high dose and high potency opioids. Many of the same mechanisms account for both central pain and opioid hyperalgesia. CONCLUSION: Newly revealed basic mechanisms suggest possible avenues for drug development and new drug therapies that could alter pain sensitization through endogenous and exogenous opioid mechanisms. Recent changes in practice such as the introduction of titration-to-effect for opioids have resulted in higher doses used in the clinic setting than ever seen previously. New basic science knowledge hints that these newer dosing practices may need to be reexamined. When pain worsens in a patient taking opioids, can we be assured that this is not because of the opioids, and can we alter this negative effect of opioids through different dosing strategies or new drug intervention? |
format | Online Article Text |
id | pubmed-5741356 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Wolters Kluwer |
record_format | MEDLINE/PubMed |
spelling | pubmed-57413562018-02-01 The dark side of opioids in pain management: basic science explains clinical observation Rivat, Cyril Ballantyne, Jane Pain Rep Inaugural Review Series INTRODUCTION: In the past 2 decades, opioids have been used increasingly for the treatment of persistent pain, and doses have tended to creep up. As basic science elucidates mechanisms of pain and analgesia, the cross talk between central pain and opioid actions becomes clearer. OBJECTIVES: We aimed to examine the published literature on basic science explaining pronociceptive opioid actions, and apply this knowledge to clinical observation. METHODS: We reviewed the existing literature on the pronociceptive actions of opioids, both preclinical and clinical studies. RESULTS: Basic science provides a rationale for the clinical observation that opioids sometimes increase rather than decrease pain. Central sensitization (hyperalgesia) underlies pain chronification, but can also be produced by high dose and high potency opioids. Many of the same mechanisms account for both central pain and opioid hyperalgesia. CONCLUSION: Newly revealed basic mechanisms suggest possible avenues for drug development and new drug therapies that could alter pain sensitization through endogenous and exogenous opioid mechanisms. Recent changes in practice such as the introduction of titration-to-effect for opioids have resulted in higher doses used in the clinic setting than ever seen previously. New basic science knowledge hints that these newer dosing practices may need to be reexamined. When pain worsens in a patient taking opioids, can we be assured that this is not because of the opioids, and can we alter this negative effect of opioids through different dosing strategies or new drug intervention? Wolters Kluwer 2016-09-08 /pmc/articles/PMC5741356/ /pubmed/29392193 http://dx.doi.org/10.1097/PR9.0000000000000570 Text en Copyright © 2016 The Authors. Published by Wolters Kluwer Health, Inc. on behalf of The International Association for the Study of Pain. All rights reserved. This is an open access article distributed under the Creative Commons Attribution License 4.0 (http://creativecommons.org/licenses/by/4.0/) (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Inaugural Review Series Rivat, Cyril Ballantyne, Jane The dark side of opioids in pain management: basic science explains clinical observation |
title | The dark side of opioids in pain management: basic science explains clinical observation |
title_full | The dark side of opioids in pain management: basic science explains clinical observation |
title_fullStr | The dark side of opioids in pain management: basic science explains clinical observation |
title_full_unstemmed | The dark side of opioids in pain management: basic science explains clinical observation |
title_short | The dark side of opioids in pain management: basic science explains clinical observation |
title_sort | dark side of opioids in pain management: basic science explains clinical observation |
topic | Inaugural Review Series |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5741356/ https://www.ncbi.nlm.nih.gov/pubmed/29392193 http://dx.doi.org/10.1097/PR9.0000000000000570 |
work_keys_str_mv | AT rivatcyril thedarksideofopioidsinpainmanagementbasicscienceexplainsclinicalobservation AT ballantynejane thedarksideofopioidsinpainmanagementbasicscienceexplainsclinicalobservation AT rivatcyril darksideofopioidsinpainmanagementbasicscienceexplainsclinicalobservation AT ballantynejane darksideofopioidsinpainmanagementbasicscienceexplainsclinicalobservation |